GSK - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer.
Business & Industry
- AZD1222 vaccine met primary efficacy endpoint in preventing COVID-19
- Pfizer and BioNTech to submit Emergency Use Authorization request today to the U.S. FDA for COVID-19 vaccine
- Pfizer and BioNTech conclude Phase 3 study of COVID-19 vaccine candidate, meeting all primary efficacy endpoints
- Moderna's COVID-19 vaccine candidate meets its primary efficacy endpoint in the first interim analysis of the Phase 3 COVE study
- Swissmedic begins rolling review of Moderna's mRNA vaccine against COVID-19 (mRNA-1273)
Research & Development
- Chinese vaccine candidate based on inactivated SARS-CoV-2 virus appears safe and induces an immune response in healthy volunteers
- Phase 2 trial of Oxford COVID-19 vaccine in healthy older adults finds it is safe and provokes immune response
- Immunological memory after cured Sars-CoV-2 infection
- European Commission approves contract with CureVac to ensure access to a potential vaccine
- Cytokine storms play a limited role in moderate-to-severe COVID-19
- Fluvoxamine may prevent serious illness in COVID-19 patients
- European Commission approves contract with BioNTech-Pfizer alliance
Conferences & Events
- CPhI Worldwide to return in 2021
- Reuters Events' Cell & Gene Therapy USA
- Total health: Build a better healthcare system
- Don't fall for the 'next best action' trap
- Locking down shape-shifting spike protein aids development of COVID-19 vaccine
- COVID-19 vaccine innovation could dramatically speed up worldwide production
- Wearable Injectors and Connected Devices Conference 2020
Regulatory Affairs
- FDA authorizes monoclonal antibodies for treatment of COVID-19
- FDA approves first treatment for COVID-19
- Investigational COVID-19 vaccine well-tolerated, generates immune response in older adults
- EMA endorses use of dexamethasone in COVID-19 patients on oxygen or mechanical ventilation
- FDA issues emergency use authorization for convalescent plasma as potential promising COVID-19 treatment